News Overview

Yes Bank has approved raising up to ₹16,000 crore through equity and debt to strengthen its capital position and fuel future growth. Despite maintaining a healthy capital adequacy ratio, the bank is proactively enhancing its financial flexibility while capping shareholder dilution at 10%.

The Advit Jewels IPO allotment status can be checked online on the NSE and BSE portals using your PAN or application number. Here's a step-by-step guide to help investors verify whether shares have been allotted.

Asian equities ended mixed as China and Hong Kong rebounded on lower oil prices, Japan edged higher, South Korea slipped slightly, and India fell below the 24K mark amid profit-taking and global uncertainty.

Dr. Reddy's Laboratories surged to a new 52-week high as optimism over its biologics pipeline, manageable USFDA observations, new product launches, and strong sector-wide momentum boosted investor confidence. Positive brokerage commentary and expectations of long-term earnings growth further strengthened the stock's rally.

The Indian stock market ended in the red on June 29, 2026, as renewed US-Iran tensions, higher crude oil prices, and profit booking weighed on investor sentiment. Nifty slipped to 23,946 while Sensex lost 372 points. Pharma stocks emerged as the top performers on biosimilar and export optimism, whereas Auto, IT, and Cement sectors witnessed broad-based selling amid cautious global cues.

Turtlemint Fintech Solutions made a muted stock market debut, listing at a discount on both NSE and BSE. Despite solid institutional interest, weak retail sentiment, negative GMP, and continued losses weighed on performance.

Suzlon Energy secures a 400 MW wind EPC order from Tata Power Renewables, boosting its order book and reinforcing its shift toward integrated EPC and DevCo-led renewable energy projects in India.

Bajaj Healthcare share price surged 15% after the company became the first in India to secure the SEC recommendation for Cenobamate tablets. The regulatory milestone is expected to strengthen its CNS portfolio and boost long-term growth prospects.

The Nifty Pharma Index outperformed the broader market by reaching a new 52-week high as pharmaceutical stocks rallied on expanding GLP-1 manufacturing, robust export demand, and positive long-term industry outlook.

Dr. Reddy's Laboratories shares climbed nearly 5% despite the USFDA issuing seven observations at its Bachupally biologics facility. Here's why investors viewed the development positively and what analysts expect next.